Meta Signs Multi-Billion Dollar AI Chip Deal With Google to Power Next-Gen AI Models 
Anthropic Resists Pentagon Pressure Over Military AI Restrictions 
Nvidia Earnings Beat Expectations as AI Demand Surges, Stock Rises on Strong Revenue Outlook 
Lynas Rare Earths Shares Surge on Strong Half-Year Earnings and Rising Global Demand 
Samsung and SK Hynix Shares Hit Record Highs as Nvidia Earnings Boost AI Chip Demand 
Trump Pushes Tech Giants to Build Power Plants to Offset AI Data Center Energy Costs 
OpenAI Hires Former Meta and Apple AI Leader Ruomin Pang Amid Intensifying AI Talent War 
CFTC Asserts Authority Over Prediction Markets Amid Insider Trading Concerns 
HSBC 2025 Earnings Beat Expectations as Wealth and Transaction Banking Drive Growth 
Toyota Plans $19 Billion Share Sale in Major Corporate Governance Reform Move 
Snowflake Forecasts Strong Fiscal 2027 Revenue Growth as Enterprise AI Demand Surges 
Coupang Reports Q4 Loss After Data Breach, Revenue Misses Estimates 
Chime Forecasts Strong 2026 Revenue Growth, Shares Jump on Profit Outlook 
Qantas Reports Record First-Half Profit as Travel Demand and New Aircraft Boost Earnings 
Woolworths Shares Surge as First-Half Profit Beats Forecasts and Full-Year Guidance Raised 
Nintendo Share Sale: MUFG and Bank of Kyoto to Sell Stakes in Strategic Unwinding 
NEW YORK, March 20, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) who purchased shares between November 10, 2016 and November 14, 2017. The action, which was filed in the United States District Court for the Eastern District of New York, alleges that the Company violated federal securities laws.
In particular, the complaints allege that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) the loan from CRG Partners III L.P. (“CRG Loan”) did not fund Synergy’s operations through 2019; (2) the Company could not access the second tranche of $100 million financing on or before February 28, 2018 without issuing dilutive equity; and (3) the Company could not access the third tranche of the CRG Loan if and when needed because terms were required to be met in order to access those tranches.
On September 5, 2017, Synergy issued a press release announcing it had closed on a “non-dilutive” $300 million loan from CRG Partners III L.P., which would be available to Synergy “when needed” and fund the Company’s operations through 2019. On November 14, 2017, Synergy revealed that terms of the loan agreement, omitted from prior statements regarding the loan, prevented it from accessing $200 million of the loan without conducting a dilutive secondary offering or offerings of shares to raise cash and, as such, the Company was conducting a secondary offering of its shares.
Shareholders have until April 10, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-c/synergy-pharmaceuticals-inc?wire=3.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
